Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women

Part of paid clinical trials in Fort Collins, Colorado.

Sponsor
Colorado State University
Study ID
NCT07406243
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Aging
  • Postmenopause

Eligibility Criteria

Sex
FEMALE
Age
60 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Mitoquinone (MitoQ) — DIETARY_SUPPLEMENT
    MitoQ is a biochemically modified form of ubiquinol Other Names: Mitoquinol
  • Placebo — DIETARY_SUPPLEMENT
    Each placebo capsule contains inert excipient and is identical in appearance

Study Details

The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are: Does MitoQ improve cerebrovascular function in postmenopausal women? If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries? Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function. Participants will: Take MitoQ (20 mg/day) or a placebo every day for 3 months Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point Keep track of symptoms and events during their treatment period to report to the study team

Key Dates

Start date
Apr 30, 2026
Status verified
Feb 2026
Primary completion
Jan 31, 2030
Completion
Jul 31, 2030

Study Design

Enrollment
86 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MitoQ, 20 mg/day
    Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
  • Placebo Comparator: Placebo
    Matched placebo capsules.

Primary Outcome Measure

Change from baseline in cerebrovascular conductance at 3 months [ Time Frame: 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Translational Physiology Laboratory within the Food Science Clinical Research LaboratoryFort CollinsColorado80526
Kevin Murray, PhD
[email protected]
(970) 491-3663
Kevin Murray, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Fort Collins, CO

By research site
Translational Physiology Laboratory within the Food Science Clinical Research Laboratory· Fort Collins, CO

Related Studies